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EVALUATING THE HEALING POTENTIAL OF PTH ON FEMORAL SHAFT 
FRACTURES IN B6, C3, AND AJ MICE 
PETER C. FOSTER 
ABSTRACT 
 Parathyroid hormone is a vital mediator of bone metabolism and studies have 
shown that exogenous treatment can enhance the fracture repair process in murine 
models. Bone remodeling is a complex process that necessitates multiple molecular and 
cellular interactions that are affected by genetic variations. These differences contribute 
to both histological and whole organ level differences of fracture healing. This study was 
performed to determine the effect of genetic variability of fracture healing in mice treated 
with parathyroid hormone during two time windows. The first window was the first 14-
day period post fracture associated with chondrogensis and the second was the day 15 to 
day 28 post fracture, which is associated with osteogenesis. Three inbred strains of mice 
A/J (AJ), C57BL/6J (B6), and C3H/HeJ (C3) that have material and structural differences 
in bone quality were given femoral shaft fractures and healing was evaluated at different 
time points post fracture using quantitative real-time polymerase chain reaction (qRT-
PCR) and qualitative radiographic analysis. Chondrogenic genes Sox9, ColIIa, aggrecan, 
and ColXa and osteogenic genes ostrix, osteocalcin, BSP, and DMP1 were examined. 
The temporal analysis of mRNA expression revealed that PTH treatment given in the first 
14 days post fracture enhanced osteogenic and chondrogenic expression in B6 mice, but 
hindered expression in AJ mice.  Treatment with PTH from post fracture day 14 to day 
28 greatly affected the osteogenic expression of B6 mice, but had little affect on other 
  v
animals. Radiographic analysis showed that each strain presents callus formation at 
approximately day 7 and reaches maximum size at day 21 post fracture. Additionally B6 
mice appear with the largest callus and AJ the smallest. Taken together, these results are 
consistent with past studies in showing that different strains of mice express a unique 
temporal and mRNA expression pattern of chondrogenic and osteogenic differentiation. 
Furthermore, these variations affect the biomechanical properties of the fracture callus 
during bone remodeling.   
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INTRODUCTION 
 
 Fracture healing is a complex process that involves cell and tissue regeneration 
and remodeling. In addition, many signaling pathways in cartilage, bone, and vasculature 
have been implicated in fracture healing (Karsenty, 2008). The majority of fractures heals 
without complication, however, approximately 5 to 10% of fractures in the United States 
are complicated by malunion or nonunion (Einhorn, 1995). Parathyroid hormone (PTH) 
has been extensively studied in animal fracture models and is a well-documented 
mediator of bone metabolism. PTH has been shown to improve bone remodeling and 
increased rates of callus formation in animal models (Della Rocca, Crist, Murtha, 2010). 
However, little is know about the effect of PTH and genetic variability on gene 
expression in murine fracture models. The aim of this study was to explore the effect of 
PTH and genetic variability on the mRNA expression of osteogenic and chondrogenic 
genes in Femoral shaft fractures. 
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Fracture Repair and Bone Remodeling 
 Fracture repair begins by a recapitulation of molecular and cellular events that 
occurred during embryonic endochondral bone formation (Gerstenfeld, Cullinane, 
Barnes, Graves, & Einhorn, 2003). Figure 1 diagrams the bone marrow, cortical and 
periosteal interaction at the fracture site.  
 
Figure 1. Important sites in fraction healing. Figure taken from Einhorn, 1995.  
 
Inflammation is the first response to a fracture injury. This occurs in the bone marrow, 
where a blood clot forms in reaction to the injury to the blood vessels in the surrounding 
area. A majority of the blood vessels in and immediately surrounding the injured area die 
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and are replaced with cytokine-releasing cells such as with macrophages, neutrophils and 
platelets within 24 hours (Strohbach, Strong, Rundle, 2011). This leads to the 
recruitment, infiltration, and proliferation of fibroblasts and skeletogenic stem cells into 
the periosteum and the formation of granulation tissue around the fracture site.  
The recruitment of both osteoprogenitor cells and mesenchymal stem cells into 
adjacent areas to the fracture site initiate intramembranous ossification and endochondral 
bone formation (Einhorn, 1998). Both processes work together to promote fracture 
healing (Gerstenfeld et al., 2006). Intramembranous ossification occurs within a few days 
post fracture, as seen in Figure 2, where the mesenchymal cells differentiate directly into 
osteoblasts without a cartilage intermediate mainly at proximal and distal sites to the 
fracture line (Gerstenfeld et al., 2006). 
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 Figure 2. Fracture repair timeline in mice. Figure taken from Strohbach, 2011.  
 
Initially the fracture site is relatively avascular thus inducing chondrogenesis. However, 
as angiogenesis occurs it becomes a vital component to healing and induces osteogenesis 
on the periosteal surface as seen in Figure 3. The timing of endochondral bone formation 
is dependent of the location and severity of the fracture and the relative stability of the 
bone and which lasts approximately two weeks within mice. Endochondral bone 
formation is characterized by the development of cartilage scaffolding or callus, which 
eventually calcifies and is later replaced by lamellar bone (Ross & Pawlina, 2010).  
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Figure 3. Normal Timeline Associated with Fracture Healing. Major steps involved in fracture 
healing are listed in the right column with the associated timeframe and illustration in the left 
column. Figure taken from Vaughn, 2008.  
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This scaffolding is made up of chondrocytes, which act to stabilize the segmented bone, 
and are derived from differentiated mesenchymal cells in areas lacking adequate blood 
supply (Gerstenfeld et al., 2003).  Following the formation of the callus and recruitment 
of blood vessels, the osteoblasts will begin to produce new bone. This leads to resorption 
of the mineralized cartilage and the transition from woven to lamellar bone. A 
histological representation of fracture repair is presented in Figure 4.  
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Figure 4. Histology Overview of Fracture Healing. Slides stained with Safarnin O and fast green show 
sagittal plane of mouse tibia fracture in transverse plane at magnification 200x, Figure taken from 
Gerstenfeld et al., 2006.  
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The Role of Parathyroid Hormone (PTH) in Osteogenesis 
 Parathyroid hormone is an 84-amino acid peptide released by chief cells at the 
parathyroid glands. Endogenous PTH acts in an endocrine fashion to maintain 
extracellular calcium levels by triggering osteoclastic bone resorption, gastrointestinal 
calcium absorption, and renal calcium and phosphate reabsorption (Ellegaard, Jorgensen, 
Schwartz, 2010). In the bone PTH binding stimulates osteoblastic activity to increase the 
expression of RANKL and inhibit the expression of osteoprotegerin (OPG) (Pool & 
Reeve, 2005). OPG binds to RANKL and blocks its interaction with RANK, RANKL’s 
receptor. Binding of RANKL to RANK initiates the formations of new osteoclasts, 
thereby enhancing bone resorption. Interestingly it has been shown in osteoporotic 
patients that daily subcutaneous injection of PTH stimulates bone formation and bone 
mineral density (Neer et al., 2001).  
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Genetic Variability in Fracture Repair 
 Twin studies estimate that approximately 70% of variability in adult bone density 
relate to polygenetic networks (Beamer et al., 1996). Considering the recognized 
biological diversity in bone quality in genetically diverse individuals, the complex role 
that these differences display in bone repair is not well understood. It is thus necessary to 
discover the role that polygenetic networks carry out and how it affects various signal 
pathways that control fracture repair. It has been suggested that genetic factors may be 
implicated in impaired fracture healing (Dimitriou, Carr, West, Markham & Giannoudis, 
2011). Previous studies have shown that osteogenic and chondrogenic mRNA expression 
varies between different genetic strains of mice C57BL/6J (B6), A/J (AJ), and C3H/HeJ 
(C3). More specifically, B6 mice were shown to have a faster progression of 
endochondral bone formation compared to the C3 and AJ strains (Jepsen et al., 2008). 
Therefore, due to the genetic variability in bone deposition and repair, additionally 
studies are needed to clarify the link between genetic variations and fracture healing.  
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Objectives  
 Previous studies have shown that PTH enhances fracture healing; however the 
molecular mechanisms behind these effects and its relation to genetic variance are 
unclear. Therefore the aim of this study is elucidate this relationship. The hypothesis of 
this study was that genetic variation would affect fracture healing in mice treated with 
PTH. This hypothesis was tested by comparing gene expression and callus appearance in 
A/J (AJ), C3H/HeK (C3), and C57BL/6J (B6) mice. Specifically, mRNA profiles for 
both osteogenic and chondrogenic genes at various time points during bone remodeling 
were used to examine temporal differences in gene expression during the fracture healing 
process. The effect of PTH treatment on fracture healing was evaluated in two groups: 
One group was treated with PTH for days 1-14 post fracture, and a second group was 
treated with PTH days 15-28 post fracture. The purpose of this was to determine when in 
the temporal progression during fracture repair process does PTH particularly effect 
regulation of known osteogenic and chondrogenic genes. 
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METHODS  
  
Experimental Design 
 
  This study was carried out in accordance with the Institutional Animal Care and 
Use Committee (IACUC) approved at Boston University School of Medicine (BUSM) 
and the Federal and United States Department of Agriculture (USDA) guidelines. A total 
of 288 inbred mice were used for this study; with 96 of each of the three strains 
C57BL/6J (B6), A/J (AJ), C3H/HeJ (C3).  These strains are known to exhibit varying 
rates of fracture healing time (Jepsen et al., 2008). Male mice were used exclusively in 
this study to eliminate possible confounding measures that are associated with the role of 
estrogen in bone metabolism and sexual dimorphism in skeletal structure (Sims et al., 
2002). These animals were obtained at approximately 8 to 10 weeks of age from Jackson 
Laboratories located in Bar Harbor, Maine and housed at the Laboratory Animal Sciences 
Center (LASC) located on the BUSM campus for the duration of the study. The LASC is 
accredited by the American Association for the Accreditation of Laboratory Animal Care 
 12 
(AAALAC). All animals were weighed at time of fracture with weights ranging from 16-
26g for AJ, 20-28g for B6, and 18-28 for C3. These weights were subsequently 
monitored until harvest to assure no mouse exhibited greater than a 20% post surgical 
reduction in weight 
 
Fracture Procedure 
All fracture procedures were carried out within a defined procedure room within 
the LASC space. Enrolled mice were anesthetized with 5% isoflourane and oxygen via a 
nose cone and maintained on 1-3% isoflurance for the duration of the procedure. The 
medial aspect of the right hindlimb was shaved with an electric shaver.  Subcutaneous 
injections of 0.1 ml of 0.5 mg/kg of Buprenex® (buprenorphine) was delivered for post-
operative pain management and a dose of 0.01 ml of 2.5 mg/kg Baytril® was 
administered prophylactically to reduce the risk of infection. The surgical area was 
aseptically prepared with Betadine® (povidone-iodine). 
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A small midline skin incision was made over the anterior aspect of the knee; a 
deep incision medial to the patella was used to expose the distal femur. The patella and 
patellar ligament were retracted laterally to expose the condylar surface of the femur and 
a 25G spinal needle was inserted into the medullary canal of the femur until it contacted 
the proximal physis, in order to stabilize the femur post fracture.  Any excess or exposed 
needle was clipped. The skin incision was then approximated with a 5.0 nylon simple 
interrupted suture.  While anesthetized, the mouse was placed in a supine position with 
the right leg pulled taught and right femur positioned on a mount underneath a modified 
fracture apparatus with a blunt blade that was used to generate the Femoral shaft fractures 
(Marturano et al., 2008).  The fracture apparatus releases a weight from a set height to 
generate the force to create the fracture (Figure 5). The height of the weight was adjusted 
for size and girth of the animal to create a transverse mid-shaft femur fracture.  
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Initial assessment of the fracture was made by gentle palpation. A dental X-ray 
unit (Gendex, Inc.) at 60kV for 0.16 seconds using Kodak Ultra Speed DF-50 Size 4 film 
was used to confirm the fracture.  These films were manually developed and examined.  
Femur with proximal, distal, or comminuted fractures or those with severe pin 
angulations were excluded from the study.  
Figure 5. Fracture apparatus. Image on the left is a computer rendering of the fracture 
apparatus with labeled components used in this study. Image on the right is the actual 
fracture apparatus, with foot pedal labled “a.” (Figure taken from Marturano et al., 2008).  
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Post-Operative Treatment 
 Mice were closely monitored post procedure until the animals regained 
consciousness and were ambulatory.  On postoperative day 1, each animal was given 
injections of buprenorphine at 0.1 mg/kg as an analgesic. Mice were examined daily for 
signs of hydration, pain, nerve damage, pin retraction, and any signs of failure to recover 
from injury until tissue harvest. 
 
Parathyroid Hormone Treatment  
 Two groups of parathyroid hormone (PTH) treatment – group 1 and group 2. 
Group 1 received daily, subcutaneous injections of 1 cc 0.75 µg human PTH (1-34, 
BACHEM ®) mixed with sterile H2O beginning on day 1 post fracture continuing until 
harvest or day 14 post fracture, whichever came first. The second treatment group 
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received injections from day 15 until harvest or day 28 post fracture, whichever came 
first. PTH was stored at –80 C.   
 
Femur Harvest  
 Fractured femurs were harvested on postoperative day 1, 3, 5, 7, 10, 14, 18, 21, 
28, and 35. Right hind limb femurs on non-fractured mice were harvested and used for 
day 0 controls. Euthanasia was accomplished by carbon dioxide inhalation.  Animals 
were placed individually a plastic chamber and closed with a stainless steel lid and 
attached flow meter. Carbon dioxide flow was set at a rate of 20% air displacement per 
minute. Terminal cardiac bleeding after carbon dioxide asphyxiation was also performed 
and the blood was placed on ice and centrifuged for 10 minutes at 14000 rpm.  A 
thoracotomy was performed and the blood plasma was extracted and frozen at -80°C for 
each animal for further studies.  X-rays were taken immediately following cervical 
dislocation using a Faxitron MX-20 Specimen Radiography System for a time of 40 
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seconds at 30kV and a distance of approximately 13 cm.  Kodak BioMax XAR Scientific 
Imaging Film was used.   
 To harvest femur, an incision was made on the posterior side of right femur and 
the skin was removed from the muscle.  The right leg was then amputated at the hip joint 
and the muscle and tissue carefully pulled away from femur as to not harm the fracture 
callus. A number 15 blade was used to cut separate the femur from the tibia and fibula. 
The spinal needle was pulled from the center canal of the femur with a needle driver.  
The resulting fracture callus was then isolated by removing both the distal and proximal 
ends of the femur and placed into an RNA-ase free 2 mL Eppendorf tube. These tubes 
were immediately placed into liquid nitrogen and stored at -80°C until the time of RNA 
extraction.  The contralateral femur of every animal was also harvested and frozen for 
future studies. 
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RNA Extraction 
 Femur samples were removed from storage in -80° C freezer and placed into 
liquid nitrogen. The bone was placed in a 2 mL tube pre-filled with 0.75 ml Qiazol Lysis 
Reagent® than snap frozen in the liquid nitrogen for approximately 15 seconds. The tube 
was removed and one 2mm stainless steel bead was added and placed into the Qiagen 
Tissue Lyser II® for lysing.  The bone was lysed for two minutes at 30 Hz and carefully 
monitored as to not lyse if the sample had thawed.  If the sample had thawed or not 
completely homogenized, the sample was placed back into the liquid nitrogen and the 
process was repeated. Once the sample was homogenized, the resulting solution was 
removed and added to a tube containing 1 mL of the Qiazol Lysis Reagent® and placed 
on ice for at least two minutes. Once all samples had been lysed, 200 µl of chloroform 
was added, subsequently vortexed, and then allowed to sit on ice for two minutes. Next, 
each sample was re-vortexed and then centrifuged at 14000 RPM at 4° C for 15 minutes.  
The aqueous phase was transferred to a new, RNase free, 1.5 ml tube and an equal 
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volume of isopropanol was added.  The tube was inverted several times until the liquid 
cleared and centrifuged again at 14000 RPM and 4° C for 30 minutes.  The supernatant 
was removed and washed with 500 µl of 70% ethanol and centrifuged at 14000 RPM and 
4° C for 5 minutes – this process was repeated once more and the ethanol was removed.  
The 1.5 ml tube was inverted on a sterile chem-wipe and left to dry the RNA containing 
pellet.  The pellet was then dissolved in 35 µl of RNase-free water and stored at -80° C. 
The RNA was tested for quality via electrophoresis on a 2% agarose gel performed at 
100V for approximately 40 minutes. Additionally, the concentration was determined by 
adding one µL of the diluted RNA to 99 µl of 10 mM Tris buffer and placed into a 
UV/Vis Spectrophotometer (Beckman Coutler DU 350). Absorbance values at 260 nm 
were recorded.  
Reverse Transcription and qPCR Quantification 
Diluted RNA from each sample was thawed on ice and a total of 2 µg was 
increased to a volume of 10.4 µl with RNase-free water contained in a 0.2 ml PCR tube. 
The reverse transcriptase reaction utilized a mixture of following reagents per sample 
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from the Taqman Reverse Transcription Kit®: MgCl2 (6.61 μl), dNTP Mix (6.0 μl), 10X 
RT Buffer (3.0 μl), and Random Hexamers (1.5 μl). The reverse transcriptase enzymes 
RNase Inhibitor (0.6 μl) and Reverse Trancriptase (1.89 μl) were added to the reagent 
mixture.  The 19.6 µl of the reverse transcription polymerase chain reaction reagents and 
enzymes were added to the 10.4 µl of RNA for a total of 30 µl and gently mixed.  The 
tubes were then placed in a thermal cycler (Eppendorf Mastercycler ®) to run the PCR 
cycle as follows: 25° C for 10 minutes, 37° C for 60 minutes, 95° C for 5 minutes, and 
held at 4° C.  The subsequent complementary DNA (cDNA) samples were then diluted 
1:50 in RNase-free water and stored at -20° C until use for qPCR. 
Quantitative real-time polymerase chain reaction (qPCR) was performed to 
amplify DNA primers of interest. Per each polymerase chain reaction, 9 µl of the diluted 
cDNA was added to 10 µl of Universal PCR Master Mix (Applied Biosystems ®) and 1 
µl of the particular primer set. A 96 well plate was used to house each reaction and 
covered with a clear adhesive film, paying careful attention to flatten the film to the 
well’s surface. The plate was placed into the centrifuge and gently spun down at 1500 
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rpm for 2 minutes to mix each sample and eliminate bubbles. The quantitative Real-Time 
polymerase chain reaction (qRT-PCR) was performed using an ABI 7700 Sequence 
Detector® (Applied Biosystems) and set up as follows: 50˚C for 2 minutes, 95˚C for 10 
minutes, 95˚C for 15 seconds, 60˚C for 1 minute and run for 40 cycles. Samples were run 
in duplicate and normalized to 18s rRNA.  The fold change in expression was normalized 
to samples from non-fractured, like-strain mice.  
 
Statistical Methods  
Statistical analysis was performed using Microsoft Excel 2008.  Mean values for 
qPCR data was computed along with standard deviation.  Graphs were generated for 
mRNA expression of selected genes, including standard deviation bars. 
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RESULTS 
Radiographic Evaluation 
Qualitative analysis of radiographs taken post-mortem, before harvest, exhibit that 
daily subcutaneous PTH treatment increases the size of the fracture callus in C3, AJ, and 
B6 mice. In all radiographic images, the distal end of the femur is located at the lower left 
corner of the image.  
 
Figure 6. AJ Radiographs. Callus fracture temporal progression from post fracture day 7 to day 35. Top 
Row: Control. Middle Row: PTH Treatment Group 1. Bottom Row: PTH Treatment Group 2. 
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Figure 7. B6 Radiographs. Callus fracture temporal progression from post fracture day 7 to day 35. Top 
Row: Control. Middle Row: PTH Treatment Group 1. Bottom Row: PTH Treatment Group 2. Omitted 
picture damaged -- excluded.  
 
 
 
 
Figure 8. C3 Radiographs. Callus fracture temporal progression from post fracture day 7 to day 35. Top 
Row: Control. Middle Row: PTH Treatment Group 1. Bottom Row: PTH Treatment Group 2. 
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The temporal progression from the initial fracture through the period of endochondral 
formation followed by resorption of the callus and then secondary bone formation with 
coupled remodeling is easily visualized radiographically (Gerstenfeld et al., 2003). The 
endochondral callus first appears at day 7, post fracture and reaches maximum size at 
post fracture day 21. The radiographs suggest that each strain undergoes callus formation, 
although B6 mice consistently show the largest callus formation and AJ the smallest. 
Additionally all strains demonstrated cartilage resorption and bone remodeling and it was 
apparent at time of harvest that PTH treated animals had denser bone. Interestingly either 
time of treatment resulted in an overall increased bone density by the end of the 
experimental period that was assessed.   
 
qPCR Analysis 
Gene expression for both osteogenic and chondrogenic genes were used to follow 
the progression of fracture repair. The chondrogenic genes associated with cartilage 
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formation and analyzed for this study in the order of the progression of their expression 
were as follows: transcription factor SOX 9, collagen type II alpha 1 (COL2A1), 
aggrecan (ACAN), and collagen type X alpha 1 (COL10A1). The aggrecan gene is 
known for its role in the production of large proteoglycan, a structural component of 
cartilage (Doege, Sasaki, & Yamada, 1991). COL10A1 is responsible for the production 
of type X collage, which is expressed in hypertrophic chondrocytes during endochondral 
ossification and COL2A1 is responsible for the production of type II collage, found 
primarily in cartilage (Gerstenfeld et al., 2006).  Finally, SOX9 is expressed in all 
chondroprogenitor cells and differentiated chondrocytes and thus controls the progression 
and initiation of chondrogenesis (Mori-Akiyama et al., 2003). Figure 9 shows the relative 
fold change compared to day 0. Gene expression profiles are presented in temporal order 
of the progression of chondrocyte differentiation and initiation of ossification.  A 
comparison of these data showed that all three strains showed varying and unique 
responses to PTH.   Within the B6 and AJ strains PTH lead to an earlier commitment to 
chondrogenesis based on Sox9 expression. Within the B6 strain, PTH induced the most 
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dramatic overall increase in chondrogenesis and shifted the period of hypotrophy to a 
slightly earlier period; however, both effects did not appear to prolong the overall period 
of chondrogenesis.  In contrast, in the AJ strain the hypertrophic period was prolonged.  
On the other hand, PTH did not seem too promote either an earlier or greater amount 
chondrogenesis in C3 strain but broadened the overall period of hypertrophy increasing 
Col10a1 to an earlier time and extending its expression to a later period as well.    
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Figure 9. qPCR Analysis of Chondrogenesis. These graphs show the temporal gene expression profiles 
of known chondrogenic genes of strain AJ, B6, and C3 mice in order of when they are expressed. The x 
axis shows days post fracture and the y axis is the fold expression compared to the control non-fractured 
femur. Error bars denote standard deviation. The control mice, PTH-1 treatment group, and PTH-2 
treatment group are shown with solid lines, dotted lines, and dashed lines respectively.  
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  Osteogenic genes evaluated include: transcription factor osterix, dentin matrix 
acidic phosphoprotein 1 (DMP1), osteocalcin, and bone sialoprotein (BSP). Osterix plays 
a vital role in the maturation of mesenchymal stem cells to osteoblasts (Zhang et al., 
2011). DMP1 signals the production of the extracellular matrix and its mineralization 
from corresponding osteoblasts (Narayanan et al., 2003). Additionally, osteocalcin aids in 
the development of bone mineralization and calcium homeostasis. Lastly, BSP encodes 
for a major structural protein of the bone matrix, including mineralized tissues like bone 
and dentin (Pesesse et al., 2014). Figure 10 shows the relative fold change in expression 
of the genes known to be involved in osteogenesis.  
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Figure 10. qPCR analysis of Osteogenesis. These graphs show the temporal gene expression profiles of 
known osteogenic genes of strain AJ, B6, and C3 mice in order of when they are expressed in endochondral 
bone formation. The x axis shows days post fracture and the y axis is the fold expression compared the 
control non-fractured femur. Errors bars denote standard deviation. The control mice, PTH-1 treatment 
group, and PTH-2 treatment group are shown with solid lines, dotted lines, and dashed lines respectively. 
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Like the chondrogenic genes, these also showed individual effects per strain to PTH. 
Osterix showed the most consistent response to PTH treatment across all the strains 
showing that both treatment periods increased its expression at later times during primary 
and secondary bone formation.  Surprisingly in the AJ strain all but DMP1 showed 
deceased expression and DMP1 was also consistently upregulated for both PTH 
treatment periods during primary and secondary periods of formations.  Once again the 
B6 strain also showed the greatest quantitative response to the PTH with all of the genes 
that were examined showing increased levels of expression. Interestingly in the C3 strain 
osteocalcin showed no overall response to PTH treatment.  
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DISCUSSION 
 
Study Findings 
 PTH mediated fracture repair has been shown to be associated with enhanced 
chondrocyte recruitment and early development of a fracture callus (Kakar et al., 2007). 
Additionally, it has been shown that different strains of mice have varying osteogenic and 
chondrogenic gene expression affecting the rate of fracture healing (Jepsen, 2008). The 
aims of this study, therefore, was to determine how the two time frames of PTH treatment 
effect fracture healing in different strains of common laboratory mice.  
 We found that chondrogenic gene expression varies between different strains of 
mice. In B6 mice, chondrogenic gene expression in the early PTH treatment group was 
enhanced as compared to the controls. The late PTH treatment group was negligibly 
affected. In AJ mice, mRNA profiles in the early PTH treatment window showed an 
earliar and less robust expression compared to the control mice excluding COLXa, which 
was slightly delayed. In C3 mice, Sox9 expression in the early PTH treatment group was 
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delayed compared to the control; however, all other gene expression of the early PTH 
treatment group versus the control mice showed similar expression. Interestingly, the late 
PTH treatment group had increased COLIIa expression in C3 mice, but seemed 
unaffected in all other gene expression profiles. Examinations of the chondrogenic 
mRNA expression profiles show chondrogenesis begins approximately one week post 
fracture.  
 The osteogenic gene expression was similar across all strains of mice. In the AJ 
mice, early PTH treatment down-regulated and delayed the expression of ostrix, 
osteocalcin, and BSP. Treatment with early PTH delayed and up-regulated DMP1 
expression compared to control. Treatment with late PTH only affected ostrix expression, 
which was upregulated compared to both the control and early PTH group.  
In B6 mice, early PTH treatment down-regulated and delayed expression of ostrix 
but upregulated expression of osteocalcin, BSP, and DMP1, albeit delayed.  The late PTH 
treatment group mRNA expression were greatly enhanced in all genes analyzed.  
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In C3 mice, the early PTH treatment showed a delayed in the onset of osteogenic 
gene expression compared to control; however, osteocalcin and DMP1 displayed minimal 
differences between groups. The late PTH treatment group was upregulated compared to 
early PTH and control groups. Examination of mRNA expression profiles show the onset 
of osteogensis begins earliest in AJ mice at approximately day 10 post fracture.  
 Taken together with radiographic analysis, this data supports previous studies that 
demonstrate the bone remodeling enhancing effect of PTH on chondrogensis. In addition, 
PTH seems to have a significant effect on the initiation of osteogenesis and the strength 
of mRNA expression in genes associated with endochondral bone formation. This study 
also is consistent with previous studies regarding genetic differences in murine fracture 
models. C3 mice demonstrate the less robust mRNA expression of examined genes and 
the latest period of osteogenesis and AJ are the most affected by PTH treatment.  
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Future Considerations 
 Fracture healing is a complex genetic trait with both genetic and environmental 
factors contributing to phenotypic properties. Individuals with genetically different 
backgrounds therefore may elicit different responses to similar skeletal stress. Employing 
different environmental perturbations in further studies, such as phosphate restriction to 
inhibit healing, could be utilized to further understand the element that regulate fracture 
healing. This study provides the first findings that suggest that the effect of PTH 
treatment will be variability regulated by the genetic background in differing strains of 
mice with highly variable bone qualities. Serum collected from each mouse during the 
terminal bleeds should be evaluated to assess if this variation is systemically reflected in 
variations in mineral metabolism.  In addition both mechanical and structural testing 
needs to be done on both fractured and contralateral femurs in PTH treated and control 
mice to determine how PTH effects the phenotypic properties of both fracture healing 
and bone mineral density and twist to break points for each time point. This would go 
further in demonstrating the potential use of PTH as a pharmacologic agent for fracture 
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healing. Finally histological preparations of the callus tissues using selective staining for 
both cartilage and mesenchymal tissues would help determine the definitive nature of 
how skeletal stem cells are directed towards endochondral tissue development in 
response to PTH.   
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